Phases

Contingent Consideration agreed for Antev shares acquired through issue of shares

Contingent Consideration agreed for Antev shares acquired by cash payment

(i) Advanced Prostate Cancer - Phase 2 success or registration

$2.00 per common share issued

$1.47 per Antev share (pro rata interest in $5,333,200)

(ii)Acute Urinary Retention Prevention - Phase 2 success or registration

$7.50 per common share issued

$5.52 per Antev share (pro rata interest in $19,999,500)

(iii) FDA NDA approval - Hormone therapy for prostate cancer

Up to $20,000,000 (subject to pro rata reduction)

$5.52 per Antev share (pro rata interest in $20,000,000

(iv) FDA NDA approval – AUR prevention

Up to $20,000,000 (subject to pro rata reduction)

$5.52 per Antev share (pro rata interest in $20,000,000)